# Inside the KLOW Peptide Stack: The Four Peptides — KPV, GHK-Cu, BPC-157, TB-500

> Inside the KLOW stack: KPV (anti-inflammatory tripeptide), GHK-Cu (copper tripeptide), BPC-157 (angiogenic pentadecapeptide), TB-500 (actin-binding fragment). Four nodes, one vial.

## In plain English

The KLOW stack is four peptides in one vial. They are not blended into a new molecule — they remain four separate compounds co-dissolved at fixed mass ratios. The standard research composition is 80 mg total: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg. Each component has its own biology, its own published literature and its own half-life. Understanding the stack means reading four separate records, not one.

## Inside the KLOW Stack: The Four Peptides

**KPV — the anti-inflammatory node (10 mg / 12.5% by mass)**

KPV is Lys-Pro-Val (lysine-proline-valine), a linear tripeptide with MW 342.44 Da and CAS number 67727-97-3. It is the C-terminal three residues of the 13-amino-acid hormone alpha-MSH. Its key biological property is substrate recognition by PepT1 (SLC15A1) — the intestinal di/tripeptide transporter — with a Km of approximately 160 microM, enabling uptake into inflamed gut epithelium and macrophages. Once inside the cell, KPV inhibits NF-kappaB p65 nuclear import and attenuates MAPK ERK/p38 signaling, reducing output of TNF-alpha, IL-6, IL-1beta and IL-8 [3].

**GHK-Cu — the matrix and copper node (50 mg / 62.5% by mass)**

GHK-Cu is glycyl-L-histidyl-L-lysine chelated 1:1 to a copper(II) ion. MW 402.92 Da, CAS 89030-95-5. First isolated from human plasma by Loren Pickart in 1973. It is the mass-dominant component, carrying the most copper per vial of any peptide stack of this type. Mechanisms include procollagen-I and procollagen-IV induction, copper delivery for lysyl oxidase-dependent collagen crosslinking, SIRT1 upregulation with STAT3 deacetylation, and a broad transcriptomic shift estimated at modulation of ~31.2% of human genes at a 50% change threshold [4][5].

**BPC-157 — the angiogenic node (10 mg / 12.5% by mass)**

BPC-157 is a synthetic 15-amino-acid peptide (sequence GEPPPGKPADDAGLV), MW 1419.53 Da, CAS 137525-51-0. Derived from a protein identified in human gastric juice. Primary mechanism: activation of the VEGFR2 / PI3K / Akt / eNOS angiogenesis cascade. Also upregulates the growth-hormone receptor in tendon fibroblasts and modulates nitric-oxide signaling through a mechanism partly resistant to L-NAME. The largest rodent literature of the four components; a 2025 IV safety pilot in two adults [6]; no approved human indication.

**TB-500 — the cytoskeletal node (10 mg / 12.5% by mass)**

TB-500 is Ac-LKKTET-Q, a synthetic N-acetylated heptapeptide (seven amino acids), MW 889.02 Da. It represents the actin-binding motif of full-length thymosin beta-4 (Tbeta4), a 43-amino-acid native protein. TB-500 sequesters G-actin (monomeric globular actin) — a step linked to cell migration and re-epithelialization. Full-length thymosin beta-4 additionally activates integrin-linked kinase and mobilizes epicardial progenitors; these activities are established for the native protein and have not been demonstrated for the short fragment. Most of the cited wound-healing data [1][8][9] are for full-length Tbeta4, not for TB-500 specifically. TB-500 / thymosin beta-4 is prohibited by WADA (S2 list, at all times) [7].

## klow stack: the combination rationale

Four non-overlapping nodes in one signaling network:

1. KPV: cytokine suppression at the transcription level (NF-kappaB / MAPK)
2. GHK-Cu: matrix remodeling and collagen-crosslinking copper supply
3. BPC-157: vascular supply (VEGFR2 angiogenesis)
4. TB-500 / Tbeta4: cytoskeletal dynamics and cell migration

The logic is that a tissue-repair cascade needs all four steps. The limitation is that no study has tested the combination, and the pharmacokinetic mismatch (the tripeptides clear faster than BPC-157) means they cannot be held at matched exposures in a single dose.

## KLOW vs glow — node comparison

The primary difference: GLOW contains GHK-Cu, BPC-157 and TB-500 but does not contain KPV. KLOW adds KPV as the fourth arm — the NF-kappaB and MAPK anti-inflammatory node that is selectively taken up into inflamed gut epithelium and immune cells via PepT1 [3].

The KPV addition makes KLOW more explicitly inflammation-targeted. GLOW's three-peptide profile addresses matrix, angiogenesis and cytoskeletal repair without a dedicated cytokine-suppressor. Neither blend has been tested as a combination in any controlled study.

---

A blueprint of the component literature — four peptides drawn against their own studies, the untested blend left as the one honest empty node.